Pfizer Inc. (PFE) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for PFE is $28.28 — 0.7% below the latest price of $28.47.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for Pfizer is anchored by its pipeline reacceleration, with 19 pivotal study starts planned across oncology, obesity, and immunology. The successful integration of Seagen is expected to strengthen Pfizer's oncology leadership, potentially contributing over $10 billion in risk-adjusted revenue by 2030 and doubling its early-stage oncology pipeline. Furthermore, Pfizer's entry into the high-growth obesity market with its GLP-1 program, berobenatide, has shown promising Phase 2b data. The company's current valuation at 10x forward earnings represents a significant discount to its peers, suggesting potential for re-rating. A strong dividend yield of 6.19% provides shareholder returns, and ongoing cost-cutting initiatives aim to save $7.2 billion by the end of 2026.
Bear Case
Pfizer faces significant headwinds, primarily from an estimated $1.5 billion impact due to the 2026 patent cliff. The decline in sales from COVID-19 related products, such as Paxlovid and Comirnaty, also presents a challenge. The company's reliance on its pipeline for future growth carries inherent risks, as evidenced by the missed primary endpoint in the Phase 3 SigVie-002 trial for metastatic non-small cell lung cancer. The elevated dividend payout ratio (over 200%) raises concerns about its sustainability. Analyst sentiment, while mixed, shows a cautious stance with some firms recently lowering price targets. The recent departure of the CFO also introduced investor uncertainty regarding the 2026 forecasts and the strategic timing of its entry into the obesity drug market.
Model-assessed risk level: Medium
Key Catalysts to Watch
Regulatory decisions for pipeline assets like HYMPAVZI (hemophilia A/B) and PADCEV (bladder cancer).
Data readouts for Berobenatide (weight management), ELREXFIO (multiple myeloma), LITFULO (vitiligo), and the Lyme Disease Vaccine Candidate.
Approximately 20 key pivotal study starts planned for 2026 across various therapeutic areas.
Further developments and market penetration of the GLP-1 obesity program.
Achievement of $7.2 billion in cost-cutting targets by the end of 2026.
Technical Backdrop
RSI-14
66.5
50-Day MA
$25.95
200-Day MA
$25.68
From 52-Wk High
-0.3%
Full momentum breakdown: Is PFE overbought or oversold?
Model Notes
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation, one of the oldest and largest pharmaceutical companies globally. After experiencing a post-pandemic decline, Pfizer's shares have shown a rebound in 2026, with an 18.58% year-to-date increase and a 15.08% rise over the past month. The company reported Q2 2026 revenue of $15 billion and adjusted diluted EPS of $0.77, exceeding consensus expectations. Pfizer is actively investing in research and development with a significant pipeline in oncology, obesity, and immunology. However, it faces challenges including substantial revenue impact from patent expirations (approximately $1.5 billion in 2026) and continued volatility in COVID-19 product sales. To mitigate these pressures, Pfizer is implementing a major cost-cutting program aiming to save $7.2 billion by the end of 2026.
In the medium term (as of August 27, 2026), Pfizer is in a rising trend channel, indicating sustained investor interest at higher prices. The stock has identified support at $27.30 and resistance at $28.60. The Relative Strength Index (RSI) is above 70, suggesting strong positive momentum, though it may also signal that the stock is becoming overbought, potentially leading to a downward reaction. Most moving averages, including the 20-day, 50-day, and 200-day simple and exponential moving averages, indicate a 'Buy' signal. The Moving Average Convergence Divergence (MACD) also suggests a 'Buy' signal.
Current Street Context
August 31, 2026The AI price target for Pfizer Inc. is $28.28. This aligns with the average analyst price target of $28.28 to $28.79, with a median of $28.00. Analyst sentiment is predominantly 'Hold,' with a significant number of 'Hold' ratings, though some firms maintain 'Buy' ratings. Key upcoming events include the next earnings report, expected around November 3, 2026. Pfizer's expanded cost-cutting program, aiming for $6.7 billion in total savings through 2029, and advancements in its obesity program and oncology portfolio are also significant. While the company raised its 2026 revenue guidance, it reaffirmed its adjusted diluted EPS guidance. It is important to remember that price targets are estimates and not guarantees.
Frequently Asked Questions
What is the price target for PFE?
How is this forecast generated?
How accurate are stock price predictions?
Will PFE stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews PFE’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on PFE
Pfizer Inc. Overview
Price, chart, analysis & financials
PFE: Overbought or Oversold?
Updated daily
PFE: Why Is It Moving?
Updated daily
PFE: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers